Success Story: Straight to Approval! NIW Granted to Chinese Instructor – No RFE Required

Client’s Testimonial:

“Thank you so much for the excellent work on my application.”

On February 7^th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for an Instructor in the Field of Nephrology (Approval Notice).

General Field: Nephrology

Position at the Time of Case Filing: Instructor

Country of Origin: China

State of Residence at the time of filing: Connecticut

Approval Notice Date: February 7^th, 2025

Processing Time: 9 months, 23 days

Case Summary:

We are pleased to share the success story of an EB-2 NIW (National Interest Waiver) approval granted to a nephrology researcher whose work is transforming how kidney diseases are diagnosed and treated. At the time of filing, the client was actively engaged in research at a U.S.-based institution, with a compelling record in internal medicine and kidney disease pathogenesis.

Research with Substantial Merit and National Importance

After evaluating this case, North America Immigration Law Group (NAILG) recognized that the petitioner’s proposed endeavor – to develop integrative kidney proteome characterization strategies using cutting-edge experimental biology techniques- holds clear national significance. Chronic kidney disease and its complications remain a pressing public health issue in the United States. The petitioner’s innovative work aims to uncover molecular mechanisms of kidney disease and identify therapeutic targets, enabling earlier detection and more effective intervention strategies. These efforts have substantial implications for reducing disease burden and healthcare costs nationwide.

Well Positioned to Advance the Proposed Endeavor

Holding a Ph.D. in internal medicine and specializing in nephrology, the petitioner has demonstrated a distinguished track record in both scholarship and translational research. At the time of filing, their portfolio included 27 peer-reviewed journal articles and 10 abstracts. This body of work has been cited over 1,010 times according to Google Scholar, underscoring the broad academic influence and adoption of their methodologies. In addition, the client has completed more than 70 reviews for scholarly journals, affirming their leadership in the field and commitment to advancing scientific knowledge.

Demonstrated Impact and Funding Support

Their projects involve novel proteomic profiling techniques that aim to map protein changes in diseased kidneys – tools that are already aiding in biomarker discovery and clinical trial design. This work contributes to the development of precision medicine approaches that can be tailored to individual patients, a priority area in U.S. healthcare research.

Independent Endorsements and Expert Support

To support the NIW petition, four letters of recommendation were submitted by respected scholars and clinicians in nephrology and internal medicine. These letters highlighted the originality, practical relevance, and national importance of the client’s work in kidney research.

“During her time in the field, she has addressed fundamental issues in kidney disease, such as AKI and CKD. Her work has direct implications for national healthcare goals.

Final Result

The I-140 NIW petition was filed under premium processing and approved within less than 10 months of filing. This favorable result, achieved without delay, affirms both the strength of the petitioner’s research and the strategic preparation provided by NAILG. We are honored to support this accomplished researcher and look forward to their continued contributions to nephrology and public health in the United States.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.